Avalon Globocare Corp (ALBT)
0.42
0.00 (0.00%)
USD |
NASDAQ |
Jun 18, 16:00
0.4202
0.00 (0.00%)
After-Hours: 07:54
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.664M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -78.68% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.550 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.372 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.57% |
Profile
| Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders. |
| URL | https://www.avalon-globocare.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 14, 2024 (est.) |
| Last Earnings Release | May. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders. |
| URL | https://www.avalon-globocare.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | |
| Industry | |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 14, 2024 (est.) |
| Last Earnings Release | May. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |